XJPX
6960
Market cap1.93bUSD
Oct 09, Last price
11,220.00JPY
1D
-0.80%
1Q
-0.09%
Jan 2017
247.91%
Name
Fukuda Denshi Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fukuda Denshi Co., Ltd. manufactures and supplies medical devices to both Japanese and international clients. Their offerings span a range of products, including resting electrocardiography equipment, data management software, and stress test apparatus. Additionally, they provide comprehensive patient monitoring systems, such as central and bedside monitors, transmitters, and central viewer workstations, as well as vascular screening solutions. The company, headquartered in Tokyo, Japan, was established in 1939.
Key people
Kotaro Fukuda
Chairman of the Board, Chief Executive Officer, Representative Director · since 2012
Daijiro Shirai
President, Chief Operating Officer, Representative Director · since 2012
Kazuo Genchi
Managing Director, Chief Director of Sales · since 2023
Haruo Ogawa
Managing Director · since 2025
Toyoharu Kanda
Executive Officer · since 2022
Kinshi Murayama
Executive Officer · since 2022
Osamu Nakata
Executive Officer · since 2022
Shinji Nomura
Executive Officer · since 2022
Koichi Saito
Executive Officer · since 2022
Hiroaki Sato
Executive Officer · since 2022
Takumi Sawada
Executive Officer · since 2022
Kenji Sawano
Executive Officer · since 2022
Hiroaki Tanihira
Executive Officer · since 2022
Shuichi Fukuda
Director · since 2023
Naoki Hisano
Managing Director, Manager of President's Office · since 2023
Independent Director · since 2025
Kazuki Furuya
Independent Director · since 2022
Hisataka Fushikuro
Independent Director · since 2023
Yukio Sato
Independent Director · since 2019
Masaaki Sugiyama
Independent Director · since 2014
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||